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Background: Adult lymphoblastic leukemia (ALL) is a malignancy that occurs in 
white blood cells. The overall cure rate in children is 85%, whereas it is only 40% in adults. 
Kefir is an important probiotic that contains many bioactive ingredients, which give it unique 
health benefits. It has been shown to control several cellular types of cancer.
Purpose: The present study investigates the effect of a cell-free fraction of kefir on CEM 
and Jurkat cells, which are human T-lymphotropic virus type I (HTLV-1)-negative malignant 
T-lymphocytes.
Methods: Cells were incubated with different kefir concentrations. The cytotoxicity of the 
  compound was evaluated by determining the percentage viability of cells. The effect of all 
the noncytotoxic concentrations of kefir on the proliferation of CEM and Jurkat cells was 
then assessed. The levels of transforming growth factor-alpha (TGF-α), transforming growth 
factor- beta1 (TGF-β1), matrix metalloproteinase-2 (MMP-2), and MMP-9 mRNA upon kefir 
treatment were then analyzed using reverse   transcriptase polymerase chain reaction (RT-PCR). 
Finally, the growth inhibitory effects of kefir on cell-cycle progression/apoptosis were assessed 
by Cell Death Detection (ELISA) and flow cytometry.
Results: The maximum cytotoxicity recorded after 48-hours treatment with 80 µg/µL kefir was only 
42% and 39% in CEM and Jurkat cells, respectively. The percent reduction in proliferation was very 
significant, and was dose-, and time-dependent. In both cell lines, kefir exhibited its antiproliferative 
effect by downregulating TGF-α and upregulating TGF-β1 mRNA expression. Upon kefir treatment,   
a marked increase in cell-cycle distribution was noted in the preG1 phase of CEM and Jurkat cells, 
indicating the proapoptotic effect of kefir, which was further confirmed by Cell Death Detection 
ELISA. However, kefir did not affect the mRNA expression of   metalloproteinases needed for 
the invasion of leukemic cell lines.
Conclusion: In conclusion, kefir is effective in inhibiting proliferation and inducing   apoptosis 
of HTLV-1-negative malignant T-lymphocytes. Therefore, further in vivo investigation is highly 
recommended.
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Introduction
Adult lymphoblastic leukemia (ALL) is a malignancy that occurs in white blood cells 
allowing them to continuously multiply in the bone marrow. ALL is common both in 
children and adults and is classified into acute or chronic subtypes depending on the 
number of abnormal T-cells in peripheral blood. Patients with ALL show symptoms 
of weakness, fatigue, anemia, weight loss, excessive bleeding, and joint pain due to 
malfunctioning of their erythrocytes, leukocytes, and platelets.1 Different treatments 
for leukemia have been developed since the 1950s. The success of a treatment is Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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measured as five-year, event-free survival rate. This survival 
rate is 70% to 83% in childhood ALL, whereas in adult ALL, 
the cure rates seldom exceed 40%. Additional work is in 
progress to obtain better results in adult patients. Pediatric and 
adult oncologists are   working together to develop a common 
treatment protocol for   adolescents and young adults.2
Kefir is produced by adding kefir grains, which are similar 
to small cauliflower florets, to pasteurized milk.3 It differs 
from other milk products such as yoghurt, for example, 
because it is fermented with a mixture of bacteria and yeast 
confined to a matrix of discrete kefir grains recovered after 
fermentation.4,5 Kefir is viscous, slightly carbonated, and 
contains small quantities of alcohol.3 It is believed that it 
contains many functional substances to which the numerous 
positive effects of kefir on health may be attributed.6 In fact, 
it has been postulated that the longevity of Bulgarian peasants 
is partially due to consumption of this fermented milk.4
Kefir grains contain bacteria and yeasts living in sym-
biosis and this special symbiotic nature has made it difficult 
to identify and study the constituent microorganisms within 
kefir grains.6 It has been reported that the bacteria and yeasts 
of kefir, when cultured separately, either were not able to grow 
in milk or showed a lower biochemical activity, also mak-
ing it more complicated to study the microbial population 
of kefir grains.3 Some of the bacteria that were identified in 
kefir include:   Lactobacillus brevis, Lb.   helveticus, Lb. kefir, 
Lb.   viridescens, Lb. casei, Lb.   kefiranofaciens, Lb.   kefirgranum, 
Lb.   parakefir, Lb.   plantarum, Lb. acidophilus, Lb. del-
brueckii, Lb. rhamnosis, Lb. paracasei, Lb.   fructirorans, 
Lb. hilgardii, Lb. fermentum, Lb. riridescens, Lactococcus 
lactis subsp. lactis, Lactococcus lactis subsp. cremoris, 
Streptococcus thermophilus, Enterococci durans, Leuconostocs 
sp., Leuconostocs mesenteroides, Acetobacter sp., Bacillus 
sp., Bacillus subtilis, Micrococcus sp., Escherechia coli, 
Kluyveromyces lactis, Kluyveromyces marxianus, and Pichia 
fermentans.3,4,7 Metabolites produced by the yeasts add to the 
taste and mouthfeel of kefir and provide a milieu for the growth 
of kefir bacteria.3 Some of the yeasts that were identified in 
kefir include: Saccharomyces sp., Saccharomyces cerevisiae, 
Saccharomyces unisporus, Saccharomyces exiguus, Saccharo-
myces turicensis, Saccharomyces delbrueckii, Saccharomyces 
dairensis, Saccharomyces unisporus, Saccharomyces lipolytica, 
  Candida pseudotropicalis, Candida friedrichii, Candida tenuis, 
Candida maris, Candida inconspicu, Candida lambica, Can-
dida   tannotelerans, Candida valida, Candida holmii, Candida 
kefir, Candida holmii, Torulaspora delbrueckii, Brettanomyces 
anomalus, Issatchenkia occidentalis, Pichia fermentans, and 
Kluyveromyces marxianus.3,7 Both bacteria and yeasts in kefir 
grains are surrounded by a polysaccharide matrix, which 
contains a water-soluble branched glucogalactan,8 produced 
by lactobacilli within the grains. The polysaccharide, named 
kefiran, is composed of a hexasaccharide-repeating unit and 
has been reported to possess many health benefits.8
The health benefits of kefir in Eastern European countries 
have been identified since early times and are linked with gen-
eral well-being there.3 Kefir has been found to stimulate the 
immune system4,9 and enhance the ability to digest lactose in 
lactose maldigestors.10 Kefir possesses antimicrobial activity 
in vitro against a wide variety of Gram-positive and Gram-
negative bacteria, as well as some fungi.3,11 Kefir also seems 
to be a promising compound in terms of the enhancement of 
mucosal resistance to gastrointestinal pathogen infection.12,13 
In addition, kefir was found to have antiallergic and anti-
mutagenic effects.8,12,14 Kefir as a complex fermented milk, 
together with its cell-free fraction (KF), was able to exert 
beneficial effects on the immune system and prevent several 
types of cancer:15 Ehrlich carcinoma or Sarcoma 180, Lewis 
lung carcinoma, E-ascites carcinoma (EC), human mammary 
cancer (MCF-7), and human T-lymphotropic virus- (HTLV)-
positive malignant T-lymphocytes.16–19
The present study aims to test the cytotoxic, antiprolifera-
tive, and proapoptotic effects of a cell-free fraction of kefir 
on human T-lymphotropic virus type 1 (HTLV-1)-negative 
leukemia cell lines.
Material and methods
Cell line and cell culture
Two HTLV-1-negative leukemia cell lines were used: CEM 
and Jurkat. CEM cells are human T-lymphoblastoid cells 
originally derived from peripheral blood of a 4-year-old 
  Caucasian female with acute lymphoblastic leukemia.20 
Jurkat cells were primarily established from the peripheral 
blood of a patient with acute lymphoblastic leukemia in 
relapse. The advantage of using Jurkat cells is that they have 
the same markers as normal lymphocytes.21
The cells were suspended in RPMI 1640 medium con-
taining 25 mM Hepes and L-glutamine supplemented with 
10% fetal bovine serum (FBS), 100 µg/mL streptomycin, 
and 100 U/mL in penicillin, and were grown in a humidified 
incubator (37°C) at 95% air and 5% CO2. Cells were split 
every two days at a ratio of 1:4. Before seeding, the cell 
viability was tested by the trypan blue dye exclusion method. 
The cells were counted using a hemocytometer according 
to the following formula: cells/mL = number of cells in five Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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squares/5 × dilution factor × volume of suspension × 104. For 
all experiments, cells were seeded at a density of 1 × 105. The 
test compound was added after 24 hours of seeding.
Primary fresh cultures of human 
lymphocytes
Human peripheral blood lymphocytes from healthy individu-
als were isolated using a Ficoll-isopaque gradient (1.077) for 
immediate growth (courtesy of the American University of 
Beirut Medical Center). These lymphocytes were grown, in 
the presence or absence of kefir, in complete growth medium 
consisting of RPMI 1640 supplemented with 20% FBS, 
2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL 
streptomycin for 24 hours. The effect of kefir on cytotoxicity 
and proliferation of the lymphocytes was determined using 
the methods described below, and the percentage change was 
determined in comparison to the control.
Preparation of cell-free fraction of kefir
Sterilized, pasteurized skimmed milk (150 mL) was 
  inoculated with kefir grains (50 g). All inoculated milk 
samples were incubated at 20°C for 24 hours in a sealed 
glass container. At the end of fermentation, the milk was 
strained to remove the kefir grains. The yeast and bacteria 
in the filtrate were removed by centrifugation (35,000 rpm 
for 10 minutes at 4°C) and filtration through a 0.22-µm 
  filter (Millipore,   Billerica, MA). The kefir filtrates were 
then solidified using a centrivap concentrator and stored 
at −20°C until required.
On the day of treatment, the solidified kefir was redissolved 
in media (RPMI 1640) and applied on the seeded cells.
Cytotoxicity
Cells were seeded into 96-well plates at a density of 
1 × 105 cells/well. After 24 hours of seeding, cells were treated 
with different concentrations of kefir or media alone for the 
controls. Cytotoxicity of kefir on the cell lines was assayed at 
6, 24, and 48 hours using two methods: 1)   Cytotoxicity Detec-
tion Kit (LDH; Roche, Mannheim, Germany) according to the 
instructions of the manufacturer. At the end of the treatment 
period, cells were centrifuged at 1400 rpm for 10 minutes at 
4°C, after which the supernatant of each well was transferred 
to a new 96-well plate. The reaction mixture, supplied with 
the kit, was then added to the wells and kept in the dark at 
room temperature for 30 minutes. This method measures the 
amount of lactate dehydrogenase (LDH) released by dead 
cells. The   conversion of tetrazolium salt into a red formazan 
dye product was measured colorimetrically at 492 nm using 
an enzyme-linked immunosorbent assay (ELISA) microplate 
reader; 2) Trypan blue exclusion method. This method 
  measures the percentage viability by visually counting the 
dark cells compared to the live bright cells.
Proliferation
Cells were seeded into 96-well plates at a density of 1 × 105 
cells/well. After 24 hours of seeding, cells were treated with 
different concentrations of kefir or media alone for the controls. 
Proliferation was measured at 6, 24, and 48 hours using two 
kits:
1.  Cell Titer96® Nonradioactive Cell Proliferation Kit 
(Roche) according to the instructions of the   manufacturer. 
At the end of the treatment period, MTT (3-[4, 
5-  dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bro-
mide) was added to all wells of the plate and kept in a 
humidified incubator (37°C) in 95% air and 5% CO2 for 
four hours, after which a solubilization buffer was added 
and kept overnight. This is an MTT-based method that 
measures the ability of the mitochondria of metabolically 
active cells to convert tetrazolium salt into a blue forma-
zan product, which is then measured colorometrically 
at 595 nm;
2.  Cell Proliferation Reagent (WST-1; Roche). At the end 
of the treatment period, water-soluble tetrazolium salt 
(WST-1) was added to the cells and kept in a humidified 
incubator (37°C) in 95% air and 5% CO2 for four hours. 
WST-1 is a tetrazolium salt that on contact with metaboli-
cally active cells is cleave to formazan by mitochondrial 
dehydrogenases. The formazan dye was then measured 
colorometrically at 450 nm. The results were expressed 
as percentage of control.
Flow cytometry
Cells were seeded at a density of 1 × 105 cells/mL in 3 mL 
of complete growth medium and, after 24 hours, treated 
with various noncytotoxic concentrations of kefir for 
24 hours. Cells were centrifuged at 1200 rpm at 4°C for 
five minutes. The pellet was then washed by resuspending 
it in 1 mL of ice-cold 1 × phosphate-buffered saline (PBS). 
Cells were centrifuged again under the same conditions 
as before and resuspended in 1 mL of 70% ethanol and 
stored at −20°C for a few days. Later, cells were thawed 
and centrifuged at 1200 rpm for five minutes, washed with 
1 mL of ice-cold 1 × PBS, centrifuged again, and then 
treated with 50 µL of RNase and incubated for one hour Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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and 15 minutes at 37°C. The cells were then pelleted at 
1200 rpm for five minutes and these pellets were washed 
with 1 mL of 1 × PBS then centrifuged and stained with 
30 µL of propidium iodide (PI). Cells were analyzed using 
a FACScan (Becton-Dickinson, San Jose, CA), which 
indicated the distribution of the cells into their respec-
tive cell-cycle phases based on their DNA content. G0/
G1 cells were 2n, S-phase cells were .2n, but ,4n, while 
G2/M cells were 4n. Cell DNA content was determined 
by CellQuest™ software (Becton-Dickinson). An increase 
in cells in the pre-G1 phase is indicative of an increase 
in apoptosis. The ratio of cells in the pre-G1 phase was 
compared to that of the control.
Cell Death Detection eLisA assay
Cell death was determined using a Cell Death detection 
ELISA (Roche). Cells were grown in RPMI 1640 complete 
growth medium as described before and treated with kefir 
for 24 hours. At the end of the experiment, the cells were 
harvested by centrifugation at 1200 rpm and the pellet was 
lysed using a lysis buffer supplied with the kit. The superna-
tant was collected after centrifugation and used as a source 
for the antigen. The wells of the plate were coated with a 
primary antihistone monoclonal antibody and incubated 
overnight at 4°C. The antigen was added then a secondary 
antibody conjugated to a peroxidase enzyme was added to 
each well. The changes in peroxidase activity were mea-
sured photometrically as optical density at 405 nm using 
2, 2′-azino-di(3-ethylbenzthiazolin-sulfonate) (ABTS) as 
a substrate. An increase in optical density of the treated 
samples in relation to the control is indicative of an increase 
in apoptosis.
RT-PCR for analysis of transforming 
growth factors and metalloproteinases
Cells were grown in 3 mL of RPMI 1640 complete growth 
medium at a cell density of 1 × 105 cells/mL and were 
treated with various noncytotoxic concentrations of kefir 
Table 1 Primer sequences used in reverse transcriptase polymerase chain reaction (RT-PCR)
Gene Size (Bp) Sequence
MMP-2 605 forward 5′-CAGTTTTTCAAGACAGA TCATAAGCG-3′, reverse 5′-TGCTCCTGCTTGAG-ATGTCG-3′
MMP-9 266 forward 5′-AAGCACATGCAGAATGAGTACCG-3′, reverse 5′-GTGGGACAGCTTCTGGTCGAT-3′;
β-Actin 550 forward 5′-ATGAAGATCCTGACCGAGCGT-3′,  reverse 5′-AACGCAGCTCAGTAACAGT-CCG-3′.
TGF-α 373 forward 5′ ATgTTgTTCCCTgCAAgTCC   3′,  reverse 3 ’ACTATGGAGAGGGGTCGCTT  5′
TGF-β1 661 forward 5′ gAAgTCACCCgCgTgCTAATgg 3′, reverse 3′ GGATGTAAACCTCGGACCTGTGTG  5′
Abbreviations: MMP, matrix metalloproteinase; TGF-α, transforming growth factor-alpha; TGF-β1, transforming growth factor-beta1; Bp, base pair.
for 24 hours. Cells were collected and stored at −80°C and 
the total RNA was extracted using an RNA extraction kit: 
NucleoSpin® RNA II kit (Macherey-Nagel GmbH and Co, 
KG, Duren, Germany) according to the manufacturer’s 
instructions.
Reverse transcriptase polymerase chain reaction (RT-
PCR) (ReddyMix™ Reverse-iT One step Kit, ABgene, 
Epsom, UK) was used to amplify RNA. Two hundred ng 
of the RNA was converted to cDNA by RT-PCR using 
(Reverse-iT™ Blend) reverse transcriptase.
PCR was conducted in 25 µL volume using oligonucle-
otide primers designed to detect the cDNA according to the 
following conditions. Table 1 shows the primers’ sequences. 
To amplify the product, the RNA template was added to 
0.5 µL of each primer (forward and reverse) (10 µM), and 
0.5 µL of reverse transcriptase (50 units/µL) were added to 
12.5 µL 2×   ReddyMix™ RT-PCR Master Mix supplied with 
the kit containing 1.25 U/50 µL of Thermoprine Plus DNA 
polymerase, dNTP mix with 0.2 mM of each nucleotide and 
1.5 mM of MgCl2, and 10 µM of each primer. This 14 µL 
mixture was added to the RNA sample and the volume was 
adjusted to 25 µL with RNase-free double distilled water. 
The PCR program for transforming growth factor-alpha 
ribonucleic acid (TGF-α RNA) was as follows: first strand 
synthesis at 47°C for 60 minutes, initial denaturation at 94°C 
for two minutes, followed by 30 cycles of denaturation for 
45 seconds at 94°C, annealing at 50°C (for TGF-α, TGF-β1, 
and matrix metalloproteinase-2 [MMP-2]) or 55°C (for 
MMP-9) for 45 seconds and elongation for 45 seconds at 
72°C with the final step at 72°C for five minutes. Conditions 
used for the amplification of β-actin were similar except that 
amplification was performed for 15 cycles and the annealing 
temperature used was 50°C. Fifteen microliters of the PCR 
products were run on 0.8% agarose gels stained with 4% 
ethidium bromide at 100 volts for 30 minutes. The resulting 
bands were visualized by ultraviolet (UV) light and photo-
graphed. β-actin was used as an internal control to ensure 
equal loading.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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statistical analyses
All experiments were carried out in triplicate. Results were 
reported as the mean value ± standard deviation. Data 
were analyzed by one-way analysis of variance (ANOVA). The 
differences between the means of treated and control groups 
were tested for significance using Fisher’s least   significant dif-
ferences at P # 0.05 (Fisher PLSD). An effect was   considered 
significant when the value (±) of mean   difference between 
groups exceeded Fisher PLSD in the one-factor ANOVA 
test.
Results
Cytotoxicity of kefir
The maximum cytotoxic value, as determined by the trypan 
blue exclusion method was 42% for CEM and 39% for Jurkat 
in the 48-hour   treatment of 80 µg/µL (Figure 1). Since the 
cytotoxicity was still below 50% and the IC50 was not reached, 
all concentrations were used to assess the effect of kefir on 
proliferation.
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Figure 1 The cytotoxicity of kefir on CEM and Jurkat cells. 
Note: error bars represent the standard deviation.
The Cytotoxicity Detection Kit (LDH) was also used 
to determine the cytotoxicity of kefir. However, the results 
obtained were not reported because kefir had a high 
  interference with the production of the red formazan dye, 
thus giving invalid values for the cytotoxicity. To test the 
effect of kefir on normal cells, T-lymphocytes obtained 
from healthy donors were treated with various concentra-
tions of kefir. Figure 2 shows that there was no significant 
necrotic effect detected by treating normal T-lymphocytes 
with kefir.
Effect of kefir on proliferation
Cells were seeded in 96-well tissue culture plates and 
treated with kefir for 6, 24, and 48 hours. The effect of kefir 
on the proliferation of leukemia cells was measured using 
two kits: one based on an MTT method that measures the 
conversion of tetrazolium salt into a formazan product, and 
another one that uses the tetrazolium salt WST-1 which, 
when in contact with metabolically active cells, becomes Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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cleaved to formazan by mitochondrial dehydrogenases. Kefir 
was found to decrease the proliferation of both cell lines in 
a dose- and time-dependent manner. The percent reduction 
in proliferation by on 60 µg/µL treatment was found to be 
around 64.83%, 88.1%, and 90.1% for 6, 24, and 48 hours 
for CEM cells, respectively, compared to 47.86%, 86.7%, and 
87.3% reduction at 6, 24, and 48 hours for Jurkat cells, respec-
tively (Figure 3). In all subsequent experiments, the treat-
ment was done by using 20, 40, and 60 µg/µL concentration 
of kefir for 24 hours. To test the effect of kefir on normal 
cells, T-lymphocytes obtained from healthy donors were 
treated with various concentrations of kefir for 24 hours; the 
maximum level in the decrease of proliferation recorded was   
only 8.2%.
Effect of kefir on cell-cycle arrest
The effect of kefir on proliferation and cell-cycle progression 
of the cell line was tested using flow cytometry analysis. Kefir 
was found to induce a G0/G1 arrest and an increase in cells 
in the pre-G1 phase indicative of an increase in apoptosis. 
In the two HTLV-1 negative cell lines, a three-fold increase in 
cells in the pre-G1 phase was observed after treatment with 
kefir for 24 hours (Figure 4).
Effect of kefir on apoptosis
Cell Death Detection ELISA assay measures the cytosolic 
histone   fragments, which are a hallmark of apoptosis, based 
on optical density. This experiment was used to further con-
firm the results obtained by flow cytometry. In both tested 
cell lines, a dose-dependent increase in apoptotic cells was 
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Figure 3 Effect of kefir on the proliferation of CEM and Jurkat cells.
Notes: The error bars represent standard deviation. Kefir causes a dose and time-dependent reduction in proliferation.
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Figure 2 Effect of kefir on the viability of normal lymphocytes from the blood of 
healthy patients.
Notes: error bars represent standard deviation. Kefir does not result in significant 
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Figure 4 Effect of kefir on the cell cycle/apoptosis by flow cytometry on CEM and Jurkat cells. Results indicate that kefir causes a G0/G1 arrest, as evidenced by the increase 
in the cells in the pre-G1 phase.
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Figure 5 Effect of kefir on apoptosis using Cell Death ELISA kit, which quantita  -
tively detects cytosolic histone-associated DNA fragments. Kefir causes an increase 
in DnA fragments, indicating an increase in apoptosis in both cell lines used.
Abbreviation: eLisA, enzyme-linked immunosorbent assay.
detected after 24-hour treatment with noncytotoxic concen-
trations of kefir (Figure 5).
Effect of kefir on transcriptional levels  
of transforming growth factors  
and metalloproteinases
The transcriptional levels of transforming growth factors 
(TGF-α and TGF-β1) and metalloproteinases (MMP-2 and 
MMP-9) were assayed using RT-PCR. The four treatments 
used in this experiment were control, 20 µg/µL, 40 µg/µL, 
and 60 µg/µL. TGFs are proteins belonging to the   family 
of cytokines that promote regulation of proliferation, 
differentiation, and apoptosis. TGF-α is a cytokine that 
induces the proliferation and replication of cells by binding 
to the epidermal growth factor receptor (EGFR),22 whereas 
TGF-β1 inhibits proliferation of activated T-lymphocytes 
by inhibiting mitosis.23   Treatment with kefir was found to 
decrease the transcriptional levels of TGF-α and increase the 
transcriptional levels of TGF-β1 in both tested cell lines in 
a dose-dependent manner (Figure 6). MMPs are gelatinases 
that degrade the extracellular matrix, thus facilitating invasion 
and metastasis of cancerous cells. Kefir had no effect on the 
expression of MMP-2 mRNA, whereas MMP-9 expression 
was not detected in both cell lines   (Figure 6). β-actin was 
used to ensure equal loading.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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which was the highest concentration of kefir used. This is in 
line with that reported by Chen et al18 where the kefir extract 
did not suppress the growth of normal human mammary cells, 
indicating that kefir contains bioactive ingredients that exert a 
growth suppressive effect that is specific to cancer cells.
To further investigate kefir’s effect on proliferation, the 
levels of TGF-α and TGF-β1 were analyzed. Kefir caused the 
downregulation of TGF-α and the upregulation of TGF-β1 in 
both cell lines used. TGFs are a large family of cytokines that 
have various effects on cells, such as regulating proliferation, 
differentiation, and apoptosis. TGF-α is a cytokine that induces 
the proliferation and replication of cells through binding to the 
epidermal growth factor receptor (EGFR).22 Binding to EGFR 
induces autophosphorylation of the receptor, triggering a phos-
phorylation cascade with some targets binding Src and JAK-2. 
Another consequence of EGFR-binding is the activation of the 
proto-oncogene Ras. It has been reported that Ras overexpres-
sion may lead to the development of skin papillomas in mice as 
well as other types of cancer.24 Furthermore, TGF-α has been 
found to inhibit apoptosis in murine gastric pit cells through the 
nuclear factor-κB (NF-κB) pathway, causing an upregulation 
of Bcl-2 antiapoptotic proteins.23 TGF-β, on the other hand, is 
a proapoptotic TGF; Saeki et al25 showed that TGF-β led to the 
induction of cell density-dependent apoptosis in human leuke-
mia HL-60 cells. TGF-β was also shown to induce Fas-mediated 
apoptosis in human T-cells,26,27 and to promote apoptosis in 
B-cells through the NF-jB/Rel pathway.28
Analysis of the cell-cycle distribution, where the inhibition 
took place due to kefir treatment, revealed that the cell-cycle 
inhibition occurred at the G0/G1 phase as a result of the increase 
in the number of cells in the Pre-G1 phase. This G0/G1 arrest 
may also indicate that kefir induces apoptosis in malignant cell 
lines. This proapoptotic effect of kefir was further confirmed 
using Cell Death Detection ELISA assay. In this technique, 
the cells were lysed and the collected supernatant, containing 
the antigen, was added to the wells of the plate coated with a 
primary antihistone monoclonal antibody. Then a secondary 
antibody (complementary to histone proteins), conjugated 
to a peroxidase enzyme, was added to each well, inducing a 
change in color upon addition of the ABTS substrate. In the 
present study, both cell lines treated with kefir exhibited an 
increase in optical density indicating an increase in apoptosis. 
In future corresponding studies, the effect of kefir on the levels 
of the proapoptotic protein Bax and p53, the cyclin-dependent 
kinase inhibitor p21, and antiapoptotic protein Bcl-2α could 
be tested.
Finally, the expression of metalloproteinases was investi-
gated to study the effect of kefir on the metastatic ability of 
Kefir conc
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Figure 6 The effect of kefir on the transcriptional level of TGF-α, TgF β1, MMP-2 
and MMP-9 in CEM and Jurkat cells.
Abbreviations: Conc, concentration; MMP, matrix metalloproteinase; TGF-α, trans 
forming growth factor-alpha; TGF-β1, transforming growth factor-beta1.
Discussion
The results obtained in this study indicate that kefir exhibits 
an antiproliferative and proapoptotic effect in HTLV-1-
negative malignant T-lymphocytes. Similar results have been 
recently reported on HUT-102 malignant T-lymphocytes 
infected with the HTLV-1 virus.19 This is also consistent with 
the previously reported antitumor effect of kefir on many 
types of cancer, such as slowing down Sarcoma 180 growth 
in mice by introducing kefir both orally and intraperitonially,16 
inhibition of pulmonary metastasis in Lewis lung carcinoma 
by orally administered polysaccharide fraction from kefir 
grains,17 reduction of proliferation and apoptosis induction 
in Sarcoma 180 in vitro,4 as well as the regression of human 
mammary cancer demonstrated by Kubow et al.5 However, 
the antitumor effect of kefir on HTLV-1-negative leukemic 
cancers has not been previously reported.
In this study, kefir induced apoptosis in cancerous cells 
at concentrations 40 µg/µL, 60 µg/µL, and 80 µg/µL. The 
cytotoxicity of the compound was analyzed by determining 
the percentage of viable cells remaining after 6, 24, and 
48 hours of incubation in order to utilize these concentrations 
as noncytotoxic. The IC50 concentration was not found, since 
kefir significantly inhibited the proliferation of both CEM 
and Jurkat cells at concentrations less than 50% cytotoxicity. 
Due to the high viscosity of kefir, it was preferable not to use 
higher concentrations in order to avoid color interference in 
the absorbance results.
The effect of kefir on cytotoxicity of normal human 
lymphocytes was also studied. Kefir is an acidic product that 
could exhibit necrotic effects on normal as well as leukemic 
lymphocytes thereby abolishing any therapeutic application 
for kefir. No cytotoxic/necrotic effect on the normal cells was 
observed, as the viability remained above 90% at 80 µg/µL, Cancer Management and Research
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leukemic cell lines. Unfortunately, MMP-9 expression was 
not detected in either of the cell lines, whereas the level of 
MMP-2 expression was not altered by kefir treatment. How-
ever, this does not rule out the possibility of kefir   affecting 
metastasis; it would be useful to determine the activity of 
metalloproteinases by on kefir treatment using zymograms 
since kefir could affect either posttranslational modifications, 
or the activity of metalloproteinases.
Conclusion
This study, along with the study on HUT-102 cells19 shows 
the beneficial effects of kefir on human T-lymphotropic virus 
type I negative and positive malignant T-cells. Kefir reduces 
proliferation and induces apoptosis of leukemic cells without 
exhibiting any significant necrotic effect on normal cells. 
Based on the above data, kefir should be further evaluated 
clinically in vivo in patients with adult T-cell leukemia.
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